Zalewski Thomas A. 4

What Happened

• Thomas A. Zalewski, Chief Legal Officer of Aquestive Therapeutics (AQST), was granted compensation on 2026-05-18 consisting of 100,000 restricted shares and 75,000 derivative awards (reported as acquisition code "A"). Both grants are reported at $0 in the filing (no cash paid at grant).
• The 100,000 are restricted stock (common stock represented by restricted shares) and the 75,000 are derivative awards (options or similar). Total immediate cash value is not shown in the filing; reported acquisition price is $0.

Key Details

• Transaction date: 2026-05-18; Form 4 filed 2026-05-19 (timely).
• Reported amounts: 100,000 restricted shares @ $0; 75,000 derivative awards @ $0.
• Vesting: Restricted stock vests in three annual installments (25% / 25% / 50%) per footnote F1. The derivative awards vest on the same 25% / 25% / 50% schedule per footnote F2.
• Shares owned after the transaction: Not specified in the provided filing excerpt.
• Filing status: Timely (no late filing indicated).
• Transaction code: A = award/grant. No 10b5-1 plan, tax-withholding, or immediate sale reported in this filing.

Context

• These awards are compensation grants to an executive and are common for retention and incentive; they do not by themselves indicate buy/sell intent in the open market.
• The derivative award is subject to vesting; those shares/options will not be fully owned/transferable until vesting conditions are met. If strike price or other economic terms for the derivative are important, they were not disclosed in the excerpt provided.